mRNA-1273 Variant-containing Formulation
ApprovedRecruiting 1 views this week 0 watching
0
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
SARS-CoV-2
Conditions
SARS-CoV-2
Trial Timeline
Sep 9, 2024 → Dec 31, 2026
NCT ID
NCT06585241About mRNA-1273 Variant-containing Formulation
mRNA-1273 Variant-containing Formulation is a approved stage product being developed by Moderna for SARS-CoV-2. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06585241. Target conditions include SARS-CoV-2.
What happened to similar drugs?
3 of 20 similar drugs in SARS-CoV-2 were approved
Approved (3) Terminated (1) Active (17)
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06585241 | Approved | Recruiting |
Competing Products
20 competing products in SARS-CoV-2
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1010 | Moderna | Phase 1 | 0 |
| mRNA-1273 | Moderna | Preclinical | 0 |
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1283 | Moderna | Phase 1 | 0 |
| mRNA-1273 | Moderna | Preclinical | 0 |
| mRNA-1083 Composition 1 Dose A Lot A | Moderna | Phase 2 | 0 |
| mRNA-1273.214 | Moderna | Phase 2 | 0 |
| SPIKEVAX | Moderna | Preclinical | 0 |
| mRNA-1273 | Moderna | Phase 3 | 0 |
| mRNA-1273 | Moderna | Phase 3 | 0 |
| mRNA-1273 | Moderna | Preclinical | 0 |
| mRNA-1083.1 | Moderna | Phase 2 | 0 |
| SPIKEVAX Bivalent | Moderna | Preclinical | 0 |
| mRNA-1083 | Moderna | Phase 3 | 0 |
| mRNA-1273 | Moderna | Phase 2 | 0 |
| mRNA-1073 | Moderna | Phase 2 | 0 |
| mRNA-1273 | Moderna | Phase 3 | 0 |
| mRNA-1273 | Moderna | Preclinical | 0 |
| mRNA-1273.211 | Moderna | Phase 3 | 0 |
| SPIKEVAX (mRNA-1273) | Moderna | Preclinical | 0 |